Poland · Delayed Price · Currency is PLN BioMaxima Statistics
Total Valuation
BioMaxima has a market cap or net worth of PLN 39.79 million. The enterprise value is 52.51 million.
| Market Cap | 39.79M |
| Enterprise Value | 52.51M |
Important Dates
The next confirmed earnings date is Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioMaxima has 4.19 million shares outstanding.
| Current Share Class | 4.19M |
| Shares Outstanding | 4.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -3.45% |
| Owned by Insiders (%) | 22.38% |
| Owned by Institutions (%) | n/a |
| Float | 2.91M |
Valuation Ratios
The trailing PE ratio is 378.98.
| PE Ratio | 378.98 |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | 16.75 |
| P/OCF Ratio | 11.79 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.09, with an EV/FCF ratio of 22.11.
| EV / Earnings | 500.10 |
| EV / Sales | 0.86 |
| EV / EBITDA | 11.09 |
| EV / EBIT | 47.48 |
| EV / FCF | 22.11 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.74 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 3.05 |
| Debt / FCF | 6.09 |
| Interest Coverage | 0.93 |
Financial Efficiency
Return on equity (ROE) is 0.22% and return on invested capital (ROIC) is 1.01%.
| Return on Equity (ROE) | 0.22% |
| Return on Assets (ROA) | 0.90% |
| Return on Invested Capital (ROIC) | 1.01% |
| Return on Capital Employed (ROCE) | 1.77% |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | 425,902 |
| Profits Per Employee | 734 |
| Employee Count | 135 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.39 |
Taxes
In the past 12 months, BioMaxima has paid 83,000 in taxes.
| Income Tax | 83,000 |
| Effective Tax Rate | 44.15% |
Stock Price Statistics
The stock price has decreased by -34.34% in the last 52 weeks. The beta is 0.30, so BioMaxima's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -34.34% |
| 50-Day Moving Average | 10.51 |
| 200-Day Moving Average | 11.98 |
| Relative Strength Index (RSI) | 33.84 |
| Average Volume (20 Days) | 2,818 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioMaxima had revenue of PLN 60.90 million and earned 105,000 in profits. Earnings per share was 0.02.
| Revenue | 60.90M |
| Gross Profit | 28.45M |
| Operating Income | 1.11M |
| Pretax Income | 188,000 |
| Net Income | 105,000 |
| EBITDA | 3.99M |
| EBIT | 1.11M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 1.74 million in cash and 14.46 million in debt, with a net cash position of -12.72 million or -3.03 per share.
| Cash & Cash Equivalents | 1.74M |
| Total Debt | 14.46M |
| Net Cash | -12.72M |
| Net Cash Per Share | -3.03 |
| Equity (Book Value) | 48.08M |
| Book Value Per Share | 11.47 |
| Working Capital | 11.06M |
Cash Flow
In the last 12 months, operating cash flow was 3.37 million and capital expenditures -999,000, giving a free cash flow of 2.38 million.
| Operating Cash Flow | 3.37M |
| Capital Expenditures | -999,000 |
| Depreciation & Amortization | 2.89M |
| Net Borrowing | -2.61M |
| Free Cash Flow | 2.38M |
| FCF Per Share | 0.57 |
Margins
Gross margin is 46.72%, with operating and profit margins of 1.82% and 0.17%.
| Gross Margin | 46.72% |
| Operating Margin | 1.82% |
| Pretax Margin | 0.31% |
| Profit Margin | 0.17% |
| EBITDA Margin | 6.56% |
| EBIT Margin | 1.82% |
| FCF Margin | 3.90% |
Dividends & Yields
BioMaxima does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 0.26% |
| FCF Yield | 5.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioMaxima has an Altman Z-Score of 2.73 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 6 |